LC
NGNE icon

Lindbrook Capital’s Neurogene NGNE Stock Holding History

Lindbrook Capital’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2
Closed – – 2166
2021
Q3 		$0 Buy
+2
New +$306 ﹤0.01% 1955

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lindbrook Capital's NGNE Position: Q4 2021 in Review

Lindbrook Capital sold out of Neurogene (NGNE) in Q4 2021, closing a stake of 2 shares.

Lindbrook Capital first reported a position in NGNE in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 80 funds tracked by Wall St. Rank hold NGNE as of Q4 2021.

  • Lindbrook Capital reported no remaining Neurogene position as of Q4 2021 after selling out during the quarter.
  • Lindbrook Capital sold 2 Neurogene shares in Q4 2021.
  • Lindbrook Capital first reported a position in Neurogene in Q3 2021 and held it in 1 quarter.
  • Lindbrook Capital's Neurogene position peaked at $0 in Q3 2021.
  • 80 funds tracked by Wall St. Rank held Neurogene as of Q4 2021.

Based on Lindbrook Capital's 13F filing for Q4 2021, filed 18 Jan 2022.